Kai-Keen Shiu is a distinguished Medical Oncology Consultant specializing in the Gastrointestinal Oncology Service. He is also an Honorary Associate Professor at the UCL Cancer Institute. Dr. Shiu treats a variety of cancers including oesophageal, stomach, small bowel, colorectal, hepatobiliary cancers, and cancers of unknown primary (CUP). He serves as the UCLH Clinical Lead for the Cancer of Unknown Primary Service and the Acute Oncology Service.Dr. Shiu’s research interests are focused on immunotherapy for gastrointestinal malignancies and CUP, emphasizing clinical trials and translational research. He is the Chief Investigator or Principal Investigator for several GI and CUP immuno-oncology Phase 2 and 3 trials, including KEYNOTE 177, KEYNOTE 859, KEYNOTE 811, KEYNOTE 975, VESTIGE, POLEM, and CUPISCO. He chairs the NCRI MUO-CUP Workstream as part of the Living With and Beyond Cancer CSG and is a member of the NCRI Colorectal Advanced and Adjuvant Disease Subgroup. Additionally, he is the Principal Investigator of the UCL-UCLH GI + CUP Cancer Translational Research Biobank and collaborates with the GI Oncology and CUP subgroups at the UCL Cancer Institute and Francis Crick Institute.Dr. Shiu is a member of several professional organizations including ASCO, ESMO, and the Association of Cancer Physicians (UK). His expertise includes chemotherapy, targeted therapy, immunotherapy, clinical trials, immunotherapy research, gastrointestinal oncology research, cancer of unknown primary research, molecular profiling with solid and liquid biopsies, and biomarker-driven clinical trial design and implementation. He is committed to education, teaching oncology to UCL medical students, as well as oncology and non-oncology junior trainees. He frequently gives talks both nationally and internationally at conferences and other hospitals, sharing best practices and future perspectives in GI oncology research, CUP, immunotherapy, and novel trial designs.